Intra-Cellular Z Score

ITCI
 Stock
  

USD 57.02  2.17  3.67%   

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Please see Intra-Cellular Ther Piotroski F Score and Intra-Cellular Ther Valuation analysis.
  
The current Market Capitalization is estimated to increase to about 4.6 B, while Capital Expenditure is projected to decrease to (351.5 K). Intra-Cellular Ther Operating Expenses is most likely to increase significantly in the upcoming years. The last year's value of Operating Expenses was reported at 361.46 Million. The current Revenues is estimated to increase to about 90.4 M, while Consolidated Income is projected to decrease to (291.6 M).

Intra-Cellular Z Score Analysis

Intra-Cellular Ther's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2021 2022 (projected)
Interest Expense33.1 K33.97 K
Gross Profit75.77 M81.75 M
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )

Intra-Cellular Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Intra-Cellular Ther is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Intra-Cellular Ther's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intra-Cellular Ther's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intra-Cellular Ther's interrelated accounts and indicators.
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

According to the company's disclosures, Intra-Cellular Ther has a Z Score of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.

Intra-Cellular Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra-Cellular Ther's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra-Cellular Ther could also be used in its relative valuation, which is a method of valuing Intra-Cellular Ther by comparing valuation metrics of similar companies.
Intra-Cellular Ther is currently under evaluation in z score category among related companies.

Intra-Cellular Ther Current Valuation Drivers

We derive many important indicators used in calculating different scores of Intra-Cellular Ther from analyzing Intra-Cellular Ther's financial statements. These drivers represent accounts that assess Intra-Cellular Ther's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Intra-Cellular Ther's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(2 M)(2.13 M)(447.64 K)(591.09 K)(554.93 K)(598.74 K)
Revenue Per Employee7.85 K5.02 K18459.4 K163.68 K176.6 K
Average Assets381.88 M400.13 M296.14 M602.7 M586.77 M498.29 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(98.62 M)(154.76 M)(147.24 M)(226.46 M)(283.59 M)(291.05 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(98.62 M)(154.76 M)(147.24 M)(226.46 M)(283.59 M)(291.05 M)
Earnings before Tax(98.83 M)(155.13 M)(147.72 M)(226.99 M)(284.12 M)(291.6 M)
Average Equity366.64 M371.23 M241.82 M544.06 M517.6 M443.81 M
Enterprise Value737.94 M553.56 M1.82 B2.28 B4.18 B4.51 B
Free Cash Flow(81.22 M)(118.56 M)(128.68 M)(230.34 M)(259.87 M)(266.71 M)
Invested Capital419.49 M265.96 M130.47 M648.16 M368.21 M332.89 M
Invested Capital Average333.71 M306.89 M193.88 M423.85 M451.48 M372.11 M
Market Capitalization790.28 M623.33 M1.9 B2.55 B4.26 B4.6 B
Tangible Asset Value471.49 M357.21 M251.19 M717.31 M489.92 M435.39 M
Working Capital455.01 M319.14 M194.1 M654.05 M413.92 M379.9 M

Intra-Cellular Ther Institutional Holders

Institutional Holdings refers to the ownership stake in Intra-Cellular Ther that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Intra-Cellular Ther's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Intra-Cellular Ther's value.
Security TypeSharesValue
Victory Capital Management IncCommon Shares1.1 M64.8 M
Pictet Asset Management SaCommon Shares1.1 M63.6 M
Timessquare Capital Management LlcCommon Shares800.8 K45.7 M
Gwk Investment Management LlcCommon Shares583.6 K33.3 M
Nicholas Investment Partners LpCommon Shares434 K24.8 M
Skandinaviska Enskilda Banken Ab PublCommon Shares383.6 K21.9 M
Lisanti Capital Growth LlcCommon Shares327.9 K18.7 M

Intra-Cellular Fundamentals

About Intra-Cellular Ther Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Intra-Cellular Ther's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra-Cellular Ther using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra-Cellular Ther based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Intra-Cellular Ther without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Intra-Cellular Ther Piotroski F Score and Intra-Cellular Ther Valuation analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.3 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.